Pooled analysis: An exploratory analysis of 5 neoadjuvant studies3
Pooled Analysis Overview
The pooled analysis included 1,763 patients with HER2+ EBC from 5 studies for which there was patient-level data, who received neoadjuvant HER2-targeted therapy plus chemotherapy and continued their anti-HER2 treatment post surgery.3
Objective
Patient-level data were pooled, with the goal to assess EFS in patients who had a pCR or residual disease and to determine if outcomes differed by treatment modality in the neoadjuvant and adjuvant settings: H → H; P + H → H; and P + H → P + H.3
The arrows indicate the time of surgery such that treatments to the left of the arrow were given prior to surgery (i.e., neoadjuvant setting) and treatments to the right of the arrow were given after surgery (i.e., adjuvant setting).3
EFS: time from the date of randomization on enrollment to the date of disease recurrence or progression or death due to any cause.3
EFS=event-free survival; H=Herceptin (patients received Herceptin HYLECTA™ [trastuzumab and hyaluronidase-oysk] subcutaneous formulation or Herceptin IV); P=PERJETA.